Clinical Trials Logo

Second-Line clinical trials

View clinical trials related to Second-Line.

Filter by:
  • None
  • Page 1

NCT ID: NCT00509964 Recruiting - Stomach Neoplasm Clinical Trials

Second-Line Irinotecan vs. ILF for AGC

Start date: May 2007
Phase: Phase 2
Study type: Interventional

Patients with recurrent or metastatic gastric cancer can benefit from palliative chemotherapy. However, over half of patients with metastatic gastric cancer who received chemotherapy failed to achieve response and even in these responders, the duration of responses was as short as a few months. Patients with metastatic gastric cancer who fail to respond or have relapse after first line chemotherapy have a grim prognosis and a standard salvage treatment is not available. We designed this phase II trial to determine the efficacy and safety of irinotecan monotherapy or combination (ILF) as second-line therapy for advanced gastric cancer.